Cargando…

A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population

We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date r...

Descripción completa

Detalles Bibliográficos
Autores principales: de Abreu, Ariane de Jesus Lopes, Cavalcante, João Roberto, de Araújo Lagos, Letícia Wigg, Caetano, Rosângela, Braga, José Ueleres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147422/
https://www.ncbi.nlm.nih.gov/pubmed/35632466
http://dx.doi.org/10.3390/vaccines10050711
_version_ 1784716803583246336
author de Abreu, Ariane de Jesus Lopes
Cavalcante, João Roberto
de Araújo Lagos, Letícia Wigg
Caetano, Rosângela
Braga, José Ueleres
author_facet de Abreu, Ariane de Jesus Lopes
Cavalcante, João Roberto
de Araújo Lagos, Letícia Wigg
Caetano, Rosângela
Braga, José Ueleres
author_sort de Abreu, Ariane de Jesus Lopes
collection PubMed
description We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population < 60 years. The evidence found supports that the vaccine indication in individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals > 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group.
format Online
Article
Text
id pubmed-9147422
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91474222022-05-29 A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population de Abreu, Ariane de Jesus Lopes Cavalcante, João Roberto de Araújo Lagos, Letícia Wigg Caetano, Rosângela Braga, José Ueleres Vaccines (Basel) Review We conducted a systematic review and a meta-analysis to assess the risk of serious adverse events in the elderly after yellow fever vaccination compared to the non-elderly population. We searched multiple databases and grey literature, and we selected research without language and publication date restrictions. Studies were analyzed in a descriptive way and meta-analyzed and expressed in terms of prevalence ratio and risk ratio with a 95% confidence interval, depending on the degree of heterogeneity found. A total of 18 studies were included and 11 were meta-analyzed. The results obtained through the meta-analysis showed a risk of serious adverse events after yellow fever vaccination three times higher for the elderly when compared to the non-elderly population and five times higher for persons > 70 years. In relation to adverse event types, viscerotropic disease associated with the yellow fever vaccine had a risk that was six times higher when compared to the population < 60 years. The evidence found supports that the vaccine indication in individuals > 60 years of age should be based on a careful analysis of individual benefit-risk assessments. The results found suggest a higher risk of events for individuals > 70 years, especially for viscerotropic and neurotropic disease associated with YFV contraindicating the use of the YFV in this age group. MDPI 2022-04-30 /pmc/articles/PMC9147422/ /pubmed/35632466 http://dx.doi.org/10.3390/vaccines10050711 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
de Abreu, Ariane de Jesus Lopes
Cavalcante, João Roberto
de Araújo Lagos, Letícia Wigg
Caetano, Rosângela
Braga, José Ueleres
A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title_full A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title_fullStr A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title_full_unstemmed A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title_short A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population
title_sort systematic review and a meta-analysis of the yellow fever vaccine in the elderly population
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147422/
https://www.ncbi.nlm.nih.gov/pubmed/35632466
http://dx.doi.org/10.3390/vaccines10050711
work_keys_str_mv AT deabreuarianedejesuslopes asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT cavalcantejoaoroberto asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT dearaujolagosleticiawigg asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT caetanorosangela asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT bragajoseueleres asystematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT deabreuarianedejesuslopes systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT cavalcantejoaoroberto systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT dearaujolagosleticiawigg systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT caetanorosangela systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation
AT bragajoseueleres systematicreviewandametaanalysisoftheyellowfevervaccineintheelderlypopulation